<DOC>
	<DOCNO>NCT00314483</DOCNO>
	<brief_summary>Mesenchymal stem cell ( MSC ) show immunosuppressive property . Following bone marrow/peripheral blood stem cell transplant , proportion patient develop condition call ‘ graft versus host disease ’ ( GVHD ) . In condition transplant cell recognize recipient foreign bring immune-mediated destruction tissue . The treatment condition use drug cause immunosuppression . A small subset patient develop severe form GVHD ( Grade III IV ) , spite best currently available treatment , associate eventual death 90 % case . The investigator propose use infusion expand MSC donor treat condition . A report approach already publish peer review journal preliminary result appear promise . The investigator also aware large trial initiate study . After get write informed consent , investigator infuse expand MSC patient develop steroid-resistant GVHD .</brief_summary>
	<brief_title>Evaluation Role Mesenchymal Stem Cells Treatment Graft Versus Host Disease</brief_title>
	<detailed_description>A single center non randomize , non blind Phase I/II clinical trial propose study role mesenchymal stem cell ( MSC ) management steroid refractory graft versus host disease ( GVHD ) follow allogeneic stem cell transplant . Patients develop grade II IV GVHD follow allogeneic stem cell transplant enrol . MSC expand donor patient develop GVHD . Expanded MSC infuse dose 1-2 million cells/kg patient steroid refractory GVHD . Response therapy study use establish criterion grade GVHD .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Informed consent obtain patient donor Any patient undergone HLAmatched relate allogeneic stem cell transplantation steroid refractory Grades IIIV acute GVHD Prednisolone 2 mg/kg/day ( equivalent dose methylprednisolone , etc . ) least one week Invasive fungal disease Active cytomegalovirus ( CMV ) /EpsteinBarr virus ( EBV ) /varicella disease Relapsed malignancy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>GVHD</keyword>
	<keyword>Treatment</keyword>
	<keyword>Steroid refractory GVHD</keyword>
</DOC>